Table 2.
Level of adherence according to the drugs or the type of regimen prescribed
| n (%) | Mean % pills taken in the past month | % nonadherent patients (P value) | |
|---|---|---|---|
| Overall | 372 (100) | 96.4 | 25.5 |
| NRTI backbone | 335 (90.1) | 96.5 | 26.0 |
| Efavirenz | 94 (25.3) | 97.8 | 17.0 (P < 0.029) |
| Nevirapine | 48 (12.9) | 94.4 | 22.9 |
| Etravirine | 14 (3.8) | 95.0 | 21.4 |
| Lopinavir | 53 (14.2) | 96.8 | 34.0 |
| Atazanavir | 101 (27.2) | 95.8 | 28.7 |
| Boosted | 81 | 95.3 | 32.1 |
| Unboosted | 20 | 98.0 | 15.0 |
| Darunavir | 42 (11.3) | 95.7 | 31.0 |
| OD | 32 | 95.9 | 31.3 |
| BID | 10 | 95.0 | 30.0 |
| fAPV/r | 11 (3.0) | 99.1 | 9.1 |
| Maraviroc | 18 (4.8) | 96.1 | 16.7 |
| Raltegravir | 64 (17.2) | 96.6 | 23.4 |
| PI class | 212 (57.0) | 96.2 | 30.2 (P < 0.018) |
| NNRTI class | 155 (41.7) | 96.5 | 19.4 (P < 0.021) |
| BID regimen | 184 (49.5) | 96.2 | 26.1 |
| OD regimen | 188 (50.5) | 96.6 | 25.0 |
| STR | 86 (23.1) | 97.8 | 17.4 (P < 0.05) |
Abbreviations: STR, single tablet regimen: tenofovir/emtricitabine/efavirenz; OD, once-daily; BID, bis-in-die; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.